RATS Sleeve Lobectomy After Neo-Chemo-IO for Non-Small Cell Lung Cancer
Summary
NIH's ClinicalTrials.gov has registered NCT07541521, a multicenter prospective observational study evaluating surgical difficulty and outcomes of robotic-assisted thoracoscopic surgery (RATS) sleeve lobectomy in patients with Stage IIB-III non-small cell lung cancer (NSCLC) following neoadjuvant chemoimmunotherapy. The study will track rates of unsuccessful surgery, associated factors, and surgeon-assessed intraoperative difficulty across multiple dimensions.
What changed
NCT07541521 has been registered on ClinicalTrials.gov as a multicenter prospective observational study of robotic-assisted thoracoscopic surgery (RATS) sleeve lobectomy in NSCLC patients after neoadjuvant chemoimmunotherapy. The study defines unsuccessful surgery as conversion to thoracotomy, incomplete resection, or major postoperative complications, and will prospectively collect clinical, intraoperative, pathological, and short-term postoperative data alongside surgeon-subjective assessments of intraoperative difficulty.
Affected parties include thoracic surgeons and oncologic surgical centers evaluating or performing sleeve lobectomy procedures on patients who have received prior neoadjuvant chemoimmunotherapy. The study's findings may inform surgical decision-making and patient selection criteria for robotic-assisted approaches in this patient population.
Archived snapshot
Apr 21, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
RATS Sleeve Lobectomy After Neo-Chemo-IO for NSCLC
Observational NCT07541521 Kind: OBSERVATIONAL Apr 21, 2026
Abstract
The goal of this multicenter prospective observational study is to learn about the surgical difficulty and outcomes of robotic-assisted sleeve lobectomy in patients with non-small cell lung cancer (NSCLC) after neoadjuvant chemoimmunotherapy. The main questions it aims to answer are:
What is the rate of unsuccessful robotic-assisted sleeve lobectomy after neoadjuvant chemoimmunotherapy?
What factors are associated with unsuccessful surgery?
How do surgeons subjectively assess intraoperative difficulty across multiple dimensions during these procedures?
In this study, unsuccessful surgery is defined as any of the following: conversion to thoracotomy, incomplete (non-R0) resection, or major postoperative complications. Participants who are scheduled to undergo curative-intent robotic-assisted sleeve lobectomy as part of their routine clinical care after neoadjuvant chemoimmunotherapy will be enrolled from multiple centers. Clinical, intraoperative, pathological, and short-term postoperative data will be collected prospectively. In addition, surgeons will be asked to provide a multidimensional subjective assessment of intraoperative difficulty, including factors such as pleural adhesions, hilar fibrosis, nodal matting, fissure completeness, and vascular inflammation or edema, to better characterize the technical challenges of surgery and their association with perioperative outcomes.
Conditions: Stage IIB-III NSCLC, Sleeve Lobectomy, Robotic Surgery, Neoadjuvant Chemoimmunotherapy
Interventions: Robot-assisted thoracoscopic surgery (RATS) sleeve lobectomy
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.